These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34635762)

  • 1. Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy.
    Ma IH; Hsia Y; Hsieh YT; Ho TC; Lai TT; Yang CM; Yang CH
    Sci Rep; 2021 Oct; 11(1):20115. PubMed ID: 34635762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy.
    Ito A; Maruyama-Inoue M; Kitajima Y; Sato S; Inoue T; Yamane S; Kadonosono K
    PLoS One; 2020; 15(6):e0235213. PubMed ID: 32579608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y; Iwahashi C; Gomi F
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy.
    Yoneda A; Wakiyama H; Kurihara J; Kitaoka T
    Eur J Ophthalmol; 2020 Nov; 30(6):1473-1479. PubMed ID: 31476891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
    Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
    Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial.
    Lee WK; Iida T; Ogura Y; Chen SJ; Wong TY; Mitchell P; Cheung GCM; Zhang Z; Leal S; Ishibashi T;
    JAMA Ophthalmol; 2018 Jul; 136(7):786-793. PubMed ID: 29801063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
    Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
    Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
    Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
    Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy.
    Kikushima W; Sakurada Y; Sugiyama A; Tanabe N; Kume A; Iijima H
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):311-316. PubMed ID: 27534663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
    Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Jin KW; Kim JH; Park JY; Park SJ; Park KH; Lee JY; Woo SJ
    Sci Rep; 2021 Jul; 11(1):14623. PubMed ID: 34272419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
    Lai K; Li Y; Zhou L; Zhong X; Huang C; Xu F; Lu L; Ge J; Jin C
    BMC Ophthalmol; 2018 Jun; 18(1):144. PubMed ID: 29925341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy.
    Jung BJ; Kim JY; Lee JH; Baek J; Lee K; Lee WK
    Sci Rep; 2019 Feb; 9(1):2055. PubMed ID: 30765771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
    Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
    Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
    JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
    Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
    BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes.
    Tanaka N; Azuma K; Aoki S; Kitamoto K; Ueda K; Fujino R; Inoue T; Obata R
    Graefes Arch Clin Exp Ophthalmol; 2024 Jun; 262(6):1811-1818. PubMed ID: 38294513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy.
    Takayama K; Kaneko H; Kataoka K; Ueno S; Chang-Hua P; Ito Y; Terasaki H
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):449-455. PubMed ID: 27538907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.
    Ngo WK; Chee WK; Tan CS; Lim TH
    BMC Ophthalmol; 2020 Apr; 20(1):150. PubMed ID: 32293353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study.
    Miyamoto N; Mandai M; Oishi A; Nakai S; Honda S; Hirashima T; Oh H; Matsumoto Y; Uenishi M; Kurimoto Y
    Br J Ophthalmol; 2019 Jun; 103(6):844-848. PubMed ID: 30077969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.